CIBC Asset Management
PTGX icon

CIBC Asset Management’s Protagonist Therapeutics PTGX Stock Holding History

CIBC Asset Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$242K Sell
1,973
-694
-26% -$72.5K ﹤0.01% 1185
2026
Q1 		$281K Hold
2,667
– – ﹤0.01% 1018
2025
Q4 		$233K Buy
+2,667
New +$218K ﹤0.01% 1126

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

CIBC Asset Management's PTGX Position: Q2 2026 in Review

CIBC Asset Management reduced its Protagonist Therapeutics (PTGX) stake by 26% in Q2 2026, selling an estimated $72.5K and leaving 1,973 shares worth $242K. The position accounts for ﹤0.01% of the portfolio, ranked #1185.

CIBC Asset Management first reported a position in PTGX in Q4 2025 and has held it in 3 quarters since. The position peaked at $281K in Q1 2026. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • CIBC Asset Management held 1,973 shares of Protagonist Therapeutics worth $242K as of Q2 2026.
  • CIBC Asset Management sold 694 Protagonist Therapeutics shares in Q2 2026, an estimated $72.5K.
  • Protagonist Therapeutics made up ﹤0.01% of CIBC Asset Management's portfolio in Q2 2026, its #1185 holding.
  • CIBC Asset Management first reported a position in Protagonist Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • CIBC Asset Management's Protagonist Therapeutics position peaked at $281K in Q1 2026.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on CIBC Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.